In the univariate analysis, all 6 IMDC prognostic factors correlated with OS.
Another analysis from the IMDC presented at GU-ASCO 2014 sought to validate the IMDC prognostic model in patients with mRCC receiving next-line targeted therapy after progression on first-line targeted therapy, and to compare the IMDC model to the 3-item Memorial Sloan Kettering Cancer Center (MSKCC) second-line prognostic model.
Researchers sought to use the IMDC database to help answer the question of whether or not CN still provides a survival benefit in patients with synchronous mRCC.
higher proportion of patients with favourable or intermediate IMDC prognostic criteria, better Karnofsky performance status [KPS], etc).
5 months for those who did not (HR adjusted for IMDC prognostic criteria: 0.